Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

Cutia Therapeutics’ CEO, Ms. Zhang Lele, has further increased her stake in the company by purchasing an additional 5,000 ...

Their presence underscored the event’s prominence and highlighted the profound influence of cross-national business ...

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with a price target of ...

The Greater Scranton Chamber of Commerce honored local businesses with SAGE Awards during the organization’s annual gala ...

Analyst Jeffrey Hung of Morgan Stanley maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), retaining the price target ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

A study on mice investigating therapeutic food for malnourished children uncovers diverse functions of a newly identified gut ...

Sir Mene Pangalos, Ph.D., joins Geoffrey von Maltzahn, Ph.D., Noubar Afeyan, Ph.D., Professor Sir Mike Stratton, and Michael Severino, M.D., on the board ...